BACKGROUND
ORCHARD (NCT03944772) was a biomarker-directed, phase II, platform study conducted to characterize resistance mechanisms and evaluate novel treatment combinations in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) following progression on first-line osimertini...
J. Goldman, J. W. Riess, Byoung Chul Cho et al.· Clinical Lung Cancer· 0 citations
It is demonstrated that intravenous administration of the poly(I:C)+R848 combination effectively reprograms TAMs, suppressing tumor progression and preventing metastasis across a variety of preclinical models of difficult-to-treat solid tumors.
Clément Anfray, A. Pensado-López, F. Castro et al.· Cancer Letters· 0 citations
Epigenetic clocks have been widely used to estimate biological age across various tissues, but their accuracy in breast tissue remains suboptimal. Pan-tissue models such as Horvath’s and Hannum’s clocks, perform poorly in predicting chronological age in breast tissue, underscoring the need for a tissue-specific approac...
L. Garma, S. Pernas, B. Fullana et al.· bioRxiv· 1 citation
This study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.
X. Le, A. Passaro, Yuan-Yuan Zhao et al.· The Lancet Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.